Unknown

Dataset Information

0

²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience.


ABSTRACT:

Purpose

Radiopeptide therapy using a somatostatin analogue labelled with a beta emitter such as (90)Y/(177)Lu-DOTATOC is a new therapeutic option in neuroendocrine cancer. Alternative treatments for patients with refractory disease are rare. Here we report the first-in-human experience with (213)Bi-DOTATOC targeted alpha therapy (TAT) in patients pretreated with beta emitters.

Methods

Seven patients with progressive advanced neuroendocrine liver metastases refractory to treatment with (90)Y/(177)Lu-DOTATOC were treated with an intraarterial infusion of (213)Bi-DOTATOC, and one patient with bone marrow carcinosis was treated with a systemic infusion of (213)Bi-DOTATOC. Haematological, kidney and endocrine toxicities were assessed according to CTCAE criteria. Radiological response was assessed with contrast-enhanced MRI and (68)Ga-DOTATOC-PET/CT. More than 2 years of follow-up were available in seven patients.

Results

The biodistribution of (213)Bi-DOTATOC was evaluable with 440 keV gamma emission scans, and demonstrated specific tumour binding. Enduring responses were observed in all treated patients. Chronic kidney toxicity was moderate. Acute haematotoxicity was even less pronounced than with the preceding beta therapies.

Conclusion

TAT can induce remission of tumours refractory to beta radiation with favourable acute and mid-term toxicity at therapeutic effective doses.

SUBMITTER: Kratochwil C 

PROVIDER: S-EPMC4525192 | BioStudies | 2014-01-01

REPOSITORIES: biostudies

Similar Datasets

2015-01-01 | S-EPMC4299770 | BioStudies
2015-01-01 | S-EPMC4631990 | BioStudies
2012-01-01 | S-EPMC3425839 | BioStudies
2015-01-01 | S-EPMC4554740 | BioStudies
2021-01-01 | S-EPMC7786468 | BioStudies
2020-01-01 | S-EPMC7859638 | BioStudies
2008-01-01 | S-EPMC2784163 | BioStudies
2018-01-01 | S-EPMC5813229 | BioStudies
2019-01-01 | S-EPMC6629729 | BioStudies
2021-01-01 | S-EPMC7865577 | BioStudies